Uroplasty — Merger or Acquisition (January 2015)
22 slides from Uroplasty's merger presentation, Jan 12, 2015
Slide 1: Creating a Medical Device Company Positioned for Growth
January 2015 Creating a Medical Device Company Positioned for Growth
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of
Slide 3: Important Additional Information About This Transaction and Where to Find It
Important Additional Information About This Transaction and Where to Find ItIn connection with the proposed merger, Vision-Sciences plans to file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of Uroplasty and Vision-Sciences that also constitutes a prosp
Slide 4: The Merger
The Merger (NASDAQ: CGNT) - Merger expected to accelerate growth -- Highly complementary organizations and capabilities - - Expands innovative product offerings in urology - - Creates platform for growth in addressable $1.3 billion flexible endoscopy market -Innovative medical device company with gr
Slide 5: Deal at a Glance
Deal at a Glance Stock-for-stock deal with fixed exchange ratio of 3.6331 shares of VSCI issued for every one share of UPIUroplasty shareholders to own 62.5% and Vision-Sciences shareholders to own 37.5% upon completion of the merger (excluding shares issuable upon conversion of notes and warrants h
Slide 6: Strategic Rationale for the Merger
Strategic Rationale for the Merger Accelerate revenue growth of combined company to a level higher than either company could achieve on its ownLeverage the strength of our combined assetsInnovative technologies in EndoSheath® and Urgent PC® Uroplasty distribution platform – 44 U.S. reps and 8 Intl.
Slide 7: Urology Market Dynamics
Urology Market Dynamics Costs of practice are rising while reimbursement is relatively stablePatient population with urologic disorders is predominantly beyond middle age (> 55 years); growth in the senior population, along with the large volume of chronic conditions, is increasing patient demand La
Slide 8: Uroplasty at a Glance
Company Summary Gross Margin Uroplasty at a Glance Note: 3/31 Fiscal Year End Total Revenue Founded in 1992NASDAQ: UPIHQ in Minnetonka, MNFY14 revenue: $24.6M119 team members at 9/30/14 Product Revenue Mix
Slide 9: Uroplasty, Inc. (UPI): Changing Care to Change Lives
Uroplasty, Inc. (UPI) Committed to Offering Transformative Treatment Options to Voiding Dysfunction Patients Uroplasty: Changing Care to Change Lives Urgent PC® The Only Commercially Available Non-Drug, Non-Surgical Treatment for Overactive Bladder (OAB)Simple and effectiveClinical validationAttract
Slide 10: AUA/SUFU Overactive Bladder Treatment Guideline
AUA/SUFU Overactive Bladder Treatment Guideline
Slide 11: 3rd Line Treatment Addressable U.S. Market
3rd Line Treatment Addressable U.S. Market Urgent PC® Adoption DriversRapidly Aging PopulationDemand for Minimally Invasive OptionsLower Risk of Adverse Events & Shorter Recovery TimesIncreasing Awareness of OABImproved Healthcare Economics
Slide 12: Vision-Sciences at a Glance
Company Summary Proprietary Technology Platform Vision-Sciences at a Glance Total Revenue Founded in 1987NASDAQ: VSCIHQ in Orangeburg, NYFY14 revenue: $17.1M98 team members at 9/30/14 Note: 3/31 Fiscal Year End
Slide 13: The Growing Need Met by EndoSheath
The Growing Need Met by EndoSheath® Cross-ContaminationA Significant Healthcare Issue“…at minimum, endoscope reprocessing problems… can lead to life-threatening infections.” Listed in the “Top 10” each of the last 5 years
Slide 14: The EndoSheath Solution
The EndoSheath® Solution Innovative technology ensures an “always ready, always sterile” endoscope
Slide 15: Vision-Sciences Comparative Reprocessing
Vision-Sciences Comparative Reprocessing
Slide 16: This Combination Will...
This Combination Will… Leverage the current capacity in Uroplasty’s 44 person U.S. sales team and 8 person International sales team; capitalize on existing relationships in urologyCreate a platform for growth in other specialties that currently perform endoscopic procedures in physician offices and
Slide 17: Cogentix Medical at a Glance
Cogentix Medical at a Glance Total Revenue Product Revenue Mix Forecasting revenue of approximately $50 million for fiscal year beginning April 1, 2015 Organization 56 direct sales reps in US and 8 direct sales reps intl.Focus on urology, with access to adjacent specialtiesScalable manufacturing
Slide 18: Cogentix Medical: Financial Profile
Cogentix Medical: Financial Profile $41.7 million in fiscal year 2014$24.6 million for Uroplasty$17.1 million for Vision-SciencesAccelerating future revenue growthTTM revenue of $43.0 million, representing growth of 10.9% 10% to 14% revenue growth anticipated for fiscal year beginning April 1, 20151
Slide 19: Depth & Breadth of Leadership Team
Depth & Breadth of Leadership TeamDistribution Platform44 U.S. Sales Reps – Uroplasty12 U.S. Sales Reps – Vision Sciences8 International Sales RepsDistributor RelationshipsFunctional ExpertiseSalesMarketingRegulatoryQuality Reimbursement Cogentix Medical: Growth Strategy Licensing & acquisition oppo
Slide 20: Cogentix Medical: Growth Strategies
Cogentix Medical: Growth Strategies GoalsAcquire innovative assets at attractive valuations Accelerate revenue growth to 15% for products in portfolio Reward shareholders through improved valuationMetricsAnticipated near-term revenue of ~ $50 millionAspire to $100 million of revenue within three yea
Slide 21: Summary Benefits to Shareholders
Summary Benefits to ShareholdersCreates Medical Device company positioned for growthGreater scale and stronger financial profileAccelerated revenue growth anticipated by leveraging existing capacity of Uroplasty sales teamExpands product offerings in UrologyExtends platform for growth in addressable
Slide 22: Cogentix Medical
Cogentix 4\ Medical